New Report Highlights Nuvectis Pharma's NXP900 Approach to NSCLC Treatment
September 16, 2024 — A new report by PESG Research highlights Nuvectis Pharma's drug candidate NXP900 and its potential role in the treatment of Non-Small Cell Lung Cancer (NSCLC). The review focuses on NXP900's unique approach to addressing critical challenges in cancer therapy resistance, positioning it as a potential significant player in NSCLC treatment.